{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:43:09Z","timestamp":1785544989264,"version":"3.56.0"},"reference-count":60,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Internet Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec sec-type=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Osteogenesis imperfecta (OI) is a rare genetic disorder characterized by bone fragility and recurrent fractures. Emerging biologics demonstrate promise by targeting bone-remodeling pathways, yet evidence for their efficacy and safety remains fragmented and heterogeneous, and no prior systematic review in OI has incorporated artificial intelligence (AI) to synthesize it.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"objective\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to systematically evaluate the efficacy and safety of novel biologics in patients with OI using an AI-assisted workflow for evidence synthesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis of interventional trials of denosumab, setrusumab, teriparatide, romosozumab, and fresolimumab. Data were retrieved from PubMed, Web of Science, Embase, ScienceDirect, the Cochrane Library, and ClinicalTrials.gov up to December 1, 2025. Eligible studies enrolled individuals with OI, reported areal bone mineral density (aBMD) and\/or fractures, and were randomized, nonrandomized, or single-arm studies; case series were excluded. As a methodological feature, GPT-4o was integrated into the workflow to perform a parallel 2-stage screening (title\/abstract and full text) and to assist with risk of bias assessment using an adapted Cochrane RoB 2 tool. The primary outcome, percentage change in aBMD, was synthesized using a random-effects meta-analysis. GPT-4o was benchmarked against human reviewers using sensitivity, specificity, and weighted Cohen \u03ba.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen trials (n=684) were systematically reviewed, of which 10 (n=333) contributed to meta-analyses. In children, denosumab produced the greatest 12-month increase in lumbar spine aBMD (25.49%, 95% CI 17.14%\u201033.84%). In adults, setrusumab at 12 months yielded the highest improvement (9.38%, 95% CI 6.5%\u201012.26%). Across trials, no biologic significantly reduced fracture incidence compared to bisphosphonates. Safety profiles varied: denosumab was associated with a high risk of hypercalcemia in children (30.95%), whereas setrusumab had no treatment-related serious adverse events. AI achieved high sensitivity in abstract (97.4%) and full-text (88.9%) screening, and reduced total screening time by over 95%. Although there was substantial agreement with humans in the quality assessment (Cohen \u03ba=0.778, 95% CI 0.710\u20100.846), the model exhibited optimism and positional biases due to reliance on probabilistic language patterns rather than structured clinical reasoning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This review is the first to synthesize and quantitatively compare skeletal outcomes across multiple biologics in OI with an AI-assisted review workflow. Denosumab and setrusumab demonstrate promising efficacy in improving lumbar spine aBMD across ages, although current evidence does not support superior fracture reduction over bisphosphonates. GPT-4o can substantially accelerate evidence synthesis but should be deployed with explicit human oversight in tasks requiring contextual understanding and clinical reasoning. These findings should be interpreted cautiously given the small and heterogeneous trial base. Taken together, our workflow presented how evidence synthesis may be scaled and operationalized in real-world rare disease research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2196\/85840","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:53:42Z","timestamp":1783716822000},"page":"e85840-e85840","source":"Crossref","is-referenced-by-count":0,"title":["Artificial Intelligence for Evidence Synthesis of Emerging Biologics to Improve Skeletal Health in Osteogenesis Imperfecta: Systematic Review and Meta-Analysis"],"prefix":"10.2196","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5058-4558","authenticated-orcid":false,"given":"Chengfei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0272-3248","authenticated-orcid":false,"given":"Zonglin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2435-9061","authenticated-orcid":false,"given":"Wing Chung","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1734-5094","authenticated-orcid":false,"given":"Zesen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1124-0398","authenticated-orcid":false,"given":"Vivien Kin Yi","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9628-3610","authenticated-orcid":false,"given":"Mariana","family":"Ramirez-Posada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2869-5751","authenticated-orcid":false,"given":"Jiyeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5856-6301","authenticated-orcid":false,"given":"Eleni","family":"Linos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-9144","authenticated-orcid":false,"given":"CL","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-0014","authenticated-orcid":false,"given":"Ian Chi Kei","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9784-6472","authenticated-orcid":false,"given":"Dong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-0591","authenticated-orcid":false,"given":"Michael","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5808-0096","authenticated-orcid":false,"given":"Dawn","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4836-7808","authenticated-orcid":false,"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"2","key":"R1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","journal-title":"J Med Genet"},{"issue":"11","key":"R2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.earlhumdev.2010.08.002","article-title":"Characterising and treating osteogenesis imperfecta","volume":"86","author":"Bishop","journal-title":"Early Hum Dev"},{"issue":"6","key":"R3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00223-012-9588-3","article-title":"Recent advances in osteogenesis imperfecta","volume":"90","author":"Cundy","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"R4","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrendo.2011.81","article-title":"New perspectives on osteogenesis imperfecta","volume":"7","author":"Forlino","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"R5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1021\/acsptsci.3c00324","article-title":"Emerging landscape of osteogenesis imperfecta pathogenesis and therapeutic approaches","volume":"7","author":"Sun","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"1","key":"R6","doi-asserted-by":"publisher","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"R7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/s0002-9343(03)00362-0","article-title":"Early discontinuation of treatment for osteoporosis","volume":"115","author":"Tosteson","journal-title":"Am J Med"},{"issue":"2","key":"R8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jpeds.2006.03.013","article-title":"Early bisphosphonate treatment in infants with severe osteogenesis imperfecta","volume":"149","author":"Antoniazzi","journal-title":"J Pediatr"},{"issue":"3","key":"R9","doi-asserted-by":"publisher","first-page":"e894","DOI":"10.1097\/MJT.0000000000000236","article-title":"Efficacy of bisphosphonates on bone mineral density and fracture rate in patients with osteogenesis imperfecta: a systematic review and meta-analysis","volume":"23","author":"Shi","journal-title":"Am J Ther"},{"issue":"6","key":"R10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.86549","article-title":"A systematic review on the efficacy of bisphosphonates on osteogenesis imperfecta","volume":"17","author":"Datir","journal-title":"Cureus"},{"issue":"2","key":"R11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.6065\/apem.2346058.029","article-title":"Denosumab use in osteogenesis imperfecta: an update on therapeutic approaches","volume":"28","author":"Majdoub","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"2","key":"R12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00198-022-06523-7","article-title":"Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders","volume":"34","author":"Marini","journal-title":"Osteoporos Int"},{"issue":"6","key":"R13","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00223-024-01188-2","article-title":"Current and developing pharmacologic agents for improving skeletal health in adults with osteogenesis imperfecta","volume":"115","author":"Liu","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"R14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI152571","article-title":"Targeting TGF-\u03b2 for treatment of osteogenesis imperfecta","volume":"132","author":"Song","journal-title":"J Clin Invest"},{"issue":"1","key":"R15","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-022-01805-4","article-title":"Machine learning computational tools to assist the performance of systematic reviews: a mapping review","volume":"22","author":"Cierco Jimenez","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"R16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227742","article-title":"Error rates of human reviewers during abstract screening in systematic reviews","volume":"15","author":"Wang","journal-title":"PLoS One"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Wang S Scells H Koopman B Zuccon G . Can ChatGPT write a good Boolean query for systematic review literature search? arXiv. Preprint posted online on Feb 3, 2023. [doi: 10.48550\/arXiv.2302.0349]","DOI":"10.1145\/3539618.3591703"},{"issue":"7","key":"R18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.20496","article-title":"Performance of a large language model in screening citations","volume":"7","author":"Oami","journal-title":"JAMA Netw Open"},{"issue":"4","key":"R19","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/jrsm.1715","article-title":"Can large language models replace humans in systematic reviews? Evaluating GPT-4\u2019s efficacy in screening and extracting data from peer-reviewed and grey literature in multiple languages","volume":"15","author":"Khraisha","journal-title":"Res Synth Methods"},{"issue":"6","key":"R20","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1093\/jamia\/ocaf063","article-title":"The emergence of large language models as tools in literature reviews: a large language model-assisted systematic review","volume":"32","author":"Scherbakov","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"R21","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-025-03138-w","article-title":"A comparative study of screening performance between Abstrackr and GPT models: systematic review and contextual analysis","volume":"25","author":"Xu","journal-title":"BMC Med Inform Decis Mak"},{"issue":"7","key":"R22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/systems11070351","article-title":"Harnessing the power of ChatGPT for automating systematic review process: methodology, case study, limitations, and future directions","volume":"11","author":"Alshami","journal-title":"Systems"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-025-02569-3","article-title":"Utilizing large language models to select literature for meta-analysis shows workload reduction while maintaining a similar recall level as manual curation","volume":"25","author":"Cai","journal-title":"BMC Med Res Methodol"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","journal-title":"BMJ"},{"issue":"1","key":"R25","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews","volume":"10","author":"Rethlefsen","journal-title":"Syst Rev"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","journal-title":"BMJ"},{"issue":"3","key":"R27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","journal-title":"Biochem Med"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","journal-title":"BMC Med Res Methodol"},{"issue":"Suppl 1","key":"R29","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-025-03119-z","article-title":"World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2025)","volume":"37","journal-title":"Aging Clin Exp Res"},{"key":"R30","unstructured":"Multicenter, single-arm study to evaluate efficacy, safety, & pharmacokinetics of denosumab in children w\/ OI (OI). ClinicalTrials.gov. Jun 24, 2015. URL: https:\/\/clinicaltrials.gov\/study\/NCT02352753 [Accessed 23-06-2026]"},{"issue":"Supplement_1","key":"R31","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf149.671","article-title":"SUN-718 results from a phase 1, open-label, ascending multiple-dose study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of romosozumab in children and adolescents with osteogenesis imperfecta and phase 3 study rationale","volume":"9","author":"El-Maouche","journal-title":"Journal of the Endocrine Society"},{"issue":"5","key":"R32","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s00223-013-9770-2","article-title":"Teriparatide treatment in adult patients with osteogenesis imperfecta type I","volume":"93","author":"Gatti","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"R33","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/jbmr\/zjae112","article-title":"Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study","volume":"39","author":"Glorieux","journal-title":"J Bone Miner Res"},{"issue":"1","key":"R34","first-page":"24","volume":"16","author":"Hoyer-Kuhn","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"2","key":"R35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.11138\/ccmbm\/2017.14.1.153","article-title":"Efficacy of teriparatide  neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study","volume":"14","author":"Leali","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"7","key":"R36","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1210\/clinem\/dgae012","article-title":"Efficacy and safety of denosumab vs zoledronic acid in OI adults: a prospective, open-label, randomized study","volume":"109","author":"Lin","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"R37","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1210\/clinem\/dgad732","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfecta\u2014the first prospective comparative study","volume":"109","author":"Liu","journal-title":"J Clin Endocrinol Metab"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1445093","article-title":"Denosumab in patients with osteogenesis imperfecta and a historical control study with alendronate","volume":"16","author":"Mei","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"R39","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","journal-title":"J Clin Invest"},{"issue":"2","key":"R40","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jocd.2018.09.001","article-title":"TBS as a tool to differentiate the impact of antiresorptives on cortical and trabecular bone in children with osteogenesis imperfecta","volume":"22","author":"Rehberg","journal-title":"J Clin Densitom"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2020.20285","article-title":"Osteogenesis imperfecta: towards an individualised interdisciplinary care strategy to improve physical activity and quality of life","volume":"150","author":"Aubry-Rozier","journal-title":"Swiss Med Wkly"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjaf112","article-title":"Bone microstructural and strength changes over one year in children with osteogenesis imperfecta are comparable to age- and sex-matched healthy controls","author":"Hosseinitabatabaei","journal-title":"J Bone Miner Res"},{"issue":"2","key":"R43","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/cge.12409","article-title":"A cross-sectional multicenter study of osteogenesis imperfecta in North America \u2013 results from the linked clinical research centers","volume":"87","author":"Patel","journal-title":"Clin Genet"},{"issue":"5","key":"R44","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.bone.2005.06.007","article-title":"High and low density in the same bone: a study on children and adolescents with mild osteogenesis imperfecta","volume":"37","author":"Rauch","journal-title":"Bone"},{"key":"R45","unstructured":"An open-label, randomized, active-controlled, phase 3 study of setrusumab compared with bisphosphonates in pediatric subjects with osteogenesis imperfecta types I, III or IV. ClinicalTrials.gov; Jun 14, 2023. URL: https:\/\/clinicaltrials.gov\/study\/NCT05768854 [Accessed 19-06-2026]"},{"issue":"19","key":"R46","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","journal-title":"N Engl J Med"},{"issue":"3","key":"R47","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/jbmr\/zjaf013","article-title":"Non-invasive quantification of bone (re)modeling dynamics in adults with osteogenesis imperfecta treated with setrusumab using timelapse high-resolution peripheral-quantitative computed tomography","volume":"40","author":"Hosseinitabatabaei","journal-title":"J Bone Miner Res"},{"key":"R48","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S14565","article-title":"Clinical utility of denosumab for treatment of bone loss in men and women","volume":"6","author":"Adler","journal-title":"Clin Interv Aging"},{"issue":"8","key":"R49","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","journal-title":"N Engl J Med"},{"issue":"2","key":"R50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020625","article-title":"Mechanisms of bone fragility: from osteogenesis imperfecta to secondary osteoporosis","volume":"22","author":"El-Gazzar","journal-title":"Int J Mol Sci"},{"issue":"9","key":"R51","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1093\/jbmr\/zjae108","article-title":"Bone matrix properties in adults with osteogenesis imperfecta are not adversely affected by setrusumab\u2014a sclerostin neutralizing antibody","volume":"39","author":"Rummler","journal-title":"J Bone Miner Res"},{"issue":"8","key":"R52","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1210\/clinem\/dgae791","article-title":"Genetics and bone mineral density predict the fractures in adults with osteogenesis imperfecta: a prospective study","volume":"110","author":"Blandin","journal-title":"J Clin Endocrinol Metab"},{"key":"R53","unstructured":"Lefebvre C Briscoe S Featherstone R Littlewood A Metzendorf MI . Chapter 4: Searching for and selecting studies. In: Higgins JP Thomas J Chandler J Cumpston M Li T , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 651. Cochrane; 2025. URL: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook [Accessed 19-06-2026]"},{"issue":"1","key":"R54","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-024-02575-4","article-title":"Title and abstract screening for literature reviews using large language models: an exploratory study in the biomedical domain","volume":"13","author":"Dennst\u00e4dt","journal-title":"Syst Rev"},{"issue":"4","key":"R55","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.241776","article-title":"Generalization bias in large language model summarization of scientific research","volume":"12","author":"Peters","journal-title":"R Soc Open Sci"},{"issue":"1","key":"R56","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/20954816.2023.2276965","article-title":"Can ChatGPT reduce human financial analysts\u2019 optimistic biases?","volume":"12","author":"Li","journal-title":"Econ Polit Stud"},{"key":"R57","unstructured":"Yu T . Benchmarking reasoning robustness in large language models. arXiv. Preprint posted online on Mar 6, 2025. [doi: 10.48550\/arXiv.2503.04550]"},{"key":"R58","doi-asserted-by":"crossref","unstructured":"Bender EM . On the dangers of stochastic parrots: can language models be too big? In: Proceedings of the 2021 ACM Conference on Fairness, Accountability, and Transparency. Association for Computing Machinery; 2021:610-623. [doi: 10.1145\/3442188.3445922]","DOI":"10.1145\/3442188.3445922"},{"key":"R59","unstructured":"Huang Y Song J Wang Z et al. Look before you leap: an exploratory study of uncertainty measurement for large language models. arXiv. Preprint posted online on Jul 16, 2023. [doi: 10.48550\/arXiv.2307.10236]"},{"issue":"3","key":"R60","doi-asserted-by":"publisher","DOI":"10.1080\/08989621.2025.2544331","article-title":"GAIDeT (Generative AI Delegation Taxonomy): a taxonomy for humans to delegate tasks to generative artificial intelligence in scientific research and publishing","volume":"33","author":"Suchikova","journal-title":"Account Res"}],"container-title":["Journal of Medical Internet Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jmir.org\/2026\/1\/e85840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:25:41Z","timestamp":1785536741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmir.org\/2026\/1\/e85840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":60,"URL":"https:\/\/doi.org\/10.2196\/85840","relation":{},"ISSN":["1438-8871"],"issn-type":[{"value":"1438-8871","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"v28i2e85840"}}